Sanofi Successfully Completes Tender Offer for Dynavax, Initiates Short-Form Merger

summarizeSummary

Sanofi's subsidiary successfully completed its tender offer for Dynavax Technologies, acquiring approximately 73.92% of outstanding shares and intends to finalize the acquisition via a short-form merger.

check_boxKey Events

• Tender Offer Successfully Completed

  The tender offer for Dynavax Technologies Corporation expired on February 9, 2026, and was not extended, with all conditions met.

• Minimum Condition Satisfied

  A total of 84,680,752 shares, representing approximately 73.92% of Dynavax's outstanding shares, were validly tendered and not withdrawn, satisfying the minimum condition for the acquisition.

• Merger to Proceed

  Sanofi's subsidiary has irrevocably accepted and will promptly pay for the tendered shares, intending to complete the acquisition of Dynavax through a short-form merger under Section 251(h) of the DGCL without a stockholder meeting.

• Dynavax Shares to be Delisted

  Following the merger, Dynavax Technologies Corporation's shares will no longer be listed on the NASDAQ Global Select Market and will be deregistered under the Exchange Act.

auto_awesomeAnalysis

This filing confirms the successful conclusion of Sanofi's tender offer for Dynavax Technologies, marking a definitive step in the acquisition process. With approximately 73.92% of Dynavax's shares tendered, the minimum condition for the offer has been met. Sanofi's subsidiary will now proceed with a short-form merger, integrating Dynavax into its operations without requiring a shareholder meeting. This finalizes a significant strategic acquisition for Sanofi, expanding its portfolio and pipeline. Investors should recognize this as the successful execution of a major M&A strategy.